B+
Bull case
25%
Probability
Target price
$15.50
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
ANNX
AnnexonANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Multiple late-2026 milestones provide unusually dense upside optionality: pivotal geographic-atrophy data, a planned GBS BLA submission, and ANX1502 proof-of-concept results. Management also reported runway into 2028 following a $200 million credit facility, and a director purchased approximately $3.3 million of stock at $5.41 in May [#SEC-8K-2026-08-12] [#SEC-FORM4-2026-05-29].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
ANX1502 proof-of-concept data may fail to validate the oral classical-complement approach or may be insufficient to support meaningful pipeline value.
Momentum
7
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $7.00 · Bull $15.50 · Bear $1.50Analysis 2026-09-11; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-09-11 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $15.50
Why
Momentum7 · Δ7d -16.7
Value41 · Δ7d -0.0
Sentiment100 · Δ7d 0.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta 0.0.
Contradictions & invalidation
- • ANX1502 proof-of-concept data may fail to validate the oral classical-complement approach or may be insufficient to support meaningful pipeline value.
- • Annexon remains a development-stage biotechnology company exposed to ongoing R&D spending, commercialization buildout costs, debt-service requirements, and potential shareholder dilution.
- • The thesis depends heavily on binary clinical and regulatory outcomes.
Catalyst clock
2026-11-30
ANX1502 proof-of-concept results
Lead driver: Sentiment · See AI snapshot
Momentum
7
9% active weight
Current posture
7d trendSoftening
Δ7d
-16.7
Δ21d
-14.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
100
62% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+6.3
Why this grade
Composite grade A. Momentum 7.4 / Value 41.2 / Sentiment 100.0
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-09-11. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$7.00
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.50
Analysis reference price unavailable
Analysis 2026-09-11 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$972.54M
Beta
1.17
Shares Out
163.84M
P/E (TTM) · Derived
-4.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-5.42
Rev YoY
-
EPS YoY
-19.9%
Gross Margin
-
Op Margin
-
Net Debt
-$212.14M
Current Ratio
5.53
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data